Back to News
Market Impact: 0.3
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Teva reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% year over year. Growth in innovative medicines was offset by lower generic-drug sales, particularly generic REVLIMID.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
TEVA-0.30
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
- Snap shares fall over 10% on third-quarter earnings miss